Dl-dapoxetine hcl(CAS: 1071929-03-7)

Dl-dapoxetine HCl (CAS: 1071929-03-7) is subject to various regulatory guidelines. In the European Union, it falls under REACH regulations, requiring identification, assessment, and authorization for substances. In the United States, FDA guidelines for drug substances and EPA regulations for environmental protection and safe handling apply. GHS classification is also relevant for its physical and health hazards.

In synthesis, there are several alternatives to Dl-dapoxetine HCl (CAS: 1071929-03-7). Common analogs include DL-Dapoxetine, and alternative reagents such as 4-(4-aminobenzoyl)piperazine and N-(3,4-dihydroxyphenyl)acetamide can be used as substitutes. These alternatives offer similar pharmacological properties but may require different synthesis conditions.

The market for Dl-dapoxetine HCl (CAS: 1071929-03-7) remains stable, with increasing research focus on its antidepressant and anti-anxiety effects. Recent trends include studies on its efficacy and safety profiles, with a growing emphasis on its potential as a treatment for depression and anxiety disorders. Market trends suggest a continued demand for this compound in pharmaceutical research and development.

Waste containing Dl-dapoxetine HCl (CAS: 1071929-03-7) should be collected in appropriate, labeled containers and stored in a secure, well-ventilated area. Incineration is a common method for disposal, ensuring complete destruction of the compound. Alternatively, professional waste disposal services can handle the waste safely, adhering to environmental protection measures and regulatory requirements. All waste management should comply with local and international guidelines to prevent environmental contamination.